Last $8.71 USD
Change Today -0.12 / -1.36%
Volume 239.9K
VSTM On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

verastem inc (VSTM) Snapshot

Open
$8.86
Previous Close
$8.83
Day High
$8.94
Day Low
$8.54
52 Week High
02/12/14 - $16.60
52 Week Low
05/8/14 - $7.10
Market Cap
225.1M
Average Volume 10 Days
151.4K
EPS TTM
$-1.91
Shares Outstanding
25.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERASTEM INC (VSTM)

verastem inc (VSTM) Related Bloomberg News

View More Bloomberg News

verastem inc (VSTM) Related Businessweek News

No Related Businessweek News Found

verastem inc (VSTM) Details

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. The company’s lead FAK inhibitor, VS-6063, is in a registration-directed trial in patients with mesothelioma; a Phase Ib trial in combination with weekly paclitaxel for patients with ovarian cancer; a Phase II study in patients with non-small cell lung cancer; and a Phase I trial in Japan in patients with solid tumors. It is also developing FAK inhibitor, VS-4718; and dual mTORC1/2 and PI3K inhibitor, VS-5584, which are in Phase I clinical trials in patients with advanced cancers. The company’s product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

30 Employees
Last Reported Date: 03/6/14
Founded in 2010

verastem inc (VSTM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $443.8K
Co-Founder, Executive Chairman and Chairman o...
Total Annual Compensation: --
Chief Medical Officer
Total Annual Compensation: $350.0K
Chief Business Officer
Total Annual Compensation: $314.7K
Compensation as of Fiscal Year 2013.

verastem inc (VSTM) Key Developments

Verastem, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Verastem, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations of $13,087,000, net loss of $13,022,000 or $0.51 loss per share against loss from operations of $10,284,000, net loss of $10,250,000 or $0.49 loss per share for the same period a year ago. For the six months, the company reported loss from operations of $26,221,000, net loss of $26,084,000 or $1.02 loss per share against loss from operations of $19,365,000, net loss of $19,287,000 or $0.94 loss per share for the same period a year ago.

Verastem, Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-17-2014 03:30 PM

Verastem, Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-17-2014 03:30 PM. Venue: InterContinental Hotel Boston, 510 Atlantic Avenu, Boston, MA 02210, United States. Speakers: Brian Sullivan, Director, Corp Development, Robert Forrester, Chief Executive Officer, President and Director.

Verastem, Inc. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014

Verastem, Inc. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014 . Venue: The Dorchester, 3 Tilney Street, London, W1K 1BJ, United Kingdom.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSTM:US $8.71 USD -0.12

VSTM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSTM.
View Industry Companies
 

Industry Analysis

VSTM

Industry Average

Valuation VSTM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERASTEM INC, please visit www.verastem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.